Streetbeat News

Products Services

ZLAB

Zai Lab announced that data from a Phase 1 study of ZL-1310 will be presented at the EORTC-NCI-AACR Symposium. The preliminary results will address the potential of ZL-1310 for treating small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:18 am

AS

Amer Sports reported that its revenue growth in Greater China exceeded 60% year-over-year during the seven-day Golden Week period. The company sees significant growth opportunities in China, especially in the outdoor segment, despite economic challenges.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:17 am

OLMA

Olema Pharmaceuticals is set to present multiple posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), highlighting its research and developments in cancer therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:16 am

MRK

Merck is set to present new research findings at IDWeek, showcasing the continued impact of its vaccines and infectious disease portfolio. This presentation could highlight the effectiveness and advancements in Merck's healthcare solutions.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:16 am

TRDA

Entrada Therapeutics presented positive clinical and preclinical data at the World Muscle Society Congress, supporting its Duchenne franchise. The data reinforces the safety of ENTR-601-44 and supports upcoming regulatory filings for Phase 2 trials.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:15 am

KYMR

Kymera Therapeutics has received FDA clearance for its investigational new drug application for KT-621. The company plans to start a Phase 1 trial in October 2024 and expects to report data in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:13 am

ALNY

Alnylam Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for Vutrisiran, targeting ATTR amyloidosis with cardiomyopathy. This submission could potentially expand the use of Vutrisiran, impacting Alnylam's market position.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:10 am

UNCY

Unicycive Therapeutics has completed the Phase 1 study of UNI-494 in healthy volunteers. The results will guide the dosing and scheduling for a potential Phase 2 trial targeting acute kidney injury.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:08 am

VKTX

Viking Therapeutics announced positive results from its Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy. The trial showed VK0214 to be safe and well-tolerated, with significant reductions in plasma levels of very long-chain fatty acids and other lipids compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:07 am

VTRS

Viatris announced successful topline results from its Phase 3 study in Japan, evaluating Effexor (Venlafaxine) for treating generalized anxiety disorder in adults. The study met its primary objective, demonstrating superior anxiolytic effects compared to a placebo at 8 weeks.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:04 am